CBL and myeloproliferative disorder: Notably, the ability of clinically used anti-leukemic drug 5-FU to accelerate exhaustion of Cbl/Cbl-b DKO HSCs and to significantly ameliorate the associated lethal MPD outcome raises the potential of a novel “exhaustion” based therapy of certain malignancies such as those associated with Cbl mutations.